Fázis II-III-IV vizsgálatok

DRC Phase II Studies
Therapeutic Area Type of Study Patient population No. of Enrolled Patients Year of Start
1. Type 2 Diabetes Phase II. -Pilot study Patients with Type 2 Diabetes 12 1999
2. Type 2 Diabetes Phase II. Patients with Type 2 Diabetes 2 2002
3. Type 2 Diabetes Phase II. Patients with Type 2 Diabetes 3 2002
4. Arteriosclerosis Phase II. Patients with Cardiovascular disease 16 2003
5. Type 2 Diabetes Phase II. Insulin Resistant Patients 42 2005
6. Type 2 Diabetes Phase II. Diabetic Patients with Hypercholesterolaemia and Moderate Proteinuria 3 2006
7. Rheumatoid Arthritis Phase II. RA patients 2 2007
8. Osteoporosis Phase II. Osteoporotic PM women 10 2008
9. Chronic Inflammation Phase II. RA patients 12 2009
10. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 3 2008
11. Anticoalgulation Phase II. Patients with Cardiovascular disease 23 2009
12. Osteoporosis Phase II. Osteoporotic PM women 15 2009
13. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 11 2009
14. Type 2 Diabetes Phase II. Patients with Type 2 Diabetes 13 2010
15. Gastroenterology Phase II. Patients with Ulcerative Collitis 2 2010
16. Type 2 Diabetes Phase II. Patients with Type 2 Diabetes 8 2010
17. Type 2 Diabetes Phase II. Patients with Type 2 Diabetes 2 2010
18. Rheumatoid Arthritis Phase II. RA patients 1 2010
19. Pulmonology Phase II. COPD patients 1 2010
20. Type 2 Diabetes Phase II. Patients with Type 2 Diabetes 8 2010
21. RA, Biology Therapy Phase II. RA patients 3 2011
22. Rheumatoid Arthritis Phase II. RA patients 44 2011
23. RA, Biology Therapy Phase II. RA patients 9 2011
24. Diabetic Nephropathy Phase II. Patients with Diabetic Nephropathy 8 2011
25. Type 2 Diabetes Phase II. Patients with Type 2 Diabetes 5 2011
26. Reumatology Phase II. Patients with Knee Osteoarthritis 18 2011
27. Diabetic Nephropathy Phase II. Patients with Diabetic Nephropathy 6 2011
28. Type 2 Diabetes Phase II. Patients with Type 2 Diabetes 8 2012
29. Diabetic Nephropathy Phase II. Diabetic Patients with Albuminuria 6 2012
30. RA, Biology Therapy Phase II. RA patients 7 2013
31. RA, Biology Therapy Phase II. RA patients 9 2013
32. RA, Biology Therapy Phase II. RA patients 3 2013
33. Type 2 Diabetes Phase II. Patients with Type 2 Diabetes 12 2013
34. RA, Biology Therapy Phase II. RA patients 9 2013
35. Hyperlipidemia Phase II. Patients with hypercholesterinaemia 9 2013
36. RA, Biology Therapy Phase II. RA patients 2 2013
37. Type 2 Diabetes Phase II. Patients with Type 2 Diabetes 3 2014
38. RA, JAK inhibitor Phase IIb RA patients 2 2014-2015
39. RA, JAK inhibitor Phase IIb RA patients 2 2014-2015
40. Crohn disease, JAK inhibitor Phase II. Crohn patients 2 2014-2015
41. Type 2 Diabetes Phase II. T2DM patients 7 2015-2016
42. RA, Biology Therapy Phase IIb RA patients 2 2015-2016
43. RA Phase IIa Patients with osteoarthritis of knee 9 2016-2017
44. Type 2 Diabetes Phase IIa T2DM patients 1 2016-2017
45. RA Phase II. RA patients 9 2016
46. RA Phase IIb RA patients 2 2015-ongoing
47. Type 2 Diabetes Phase II. T2DM patients 63 2015-2017
48. Hyperlipidemia Phase II. Hypertrigliceridemia 12 2016-ongoing
49. Type 2 Diabetes Phase II. T2DM patients 10 2017-2018
50. RA Phase IIb RA patients 2 2016-2018
51. Diabetic Nephropathy Phase IIa T2DM neurpathic patients 6 2017-2018
52. Gastroenterology Phase IIa UC patient 1 2018
53. CKD Phase II. Hypertension with CKD 2 2017-2018
54. Type 2 Diabetes Phase IIa T2DM patients 7 2018
55. Gastroenterology Phase IIa UC patient 1 2018-ongoing
56. Diabetic Nephropathy Phase II. Patients with painful diabetic neuropathy 4 2018-ongoing
57. Type 2 Diabetes Phase II. T2DM patients 5 2018-ongoing
58. Rhematology Phase IIa Osteoarthritis of knee patients 2 2018
DRC Phase III Studies
Therapeutic Area Type of Study Patient population No. of Enrolled Patients Year of Start
1. Osteoporosis Phase III. Osteoporotic PM women 13 1997
2. Osteoporosis Phase III. Osteoporotic PM women 10 1999
3. Coronary Artery Disease Phase III. Patients with Coronary Artery Disease 7 1999
4. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 17 2000
5. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 12 2001
6. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 85 2001
7. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 64 2001
8. Osteoporosis Phase III. Osteoporotic PM women 63 2002
9. Osteoporosis Phase III. Osteoporotic PM women 36 2002
10. Osteoporosis Phase III. Osteoporotic PM women 22 2002
11. Diabetic Retinopathy Phase III. Diabetic patients with retinopathy 14 2002
12. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 6 2002
13. Osteoporosis Phase III. Osteoporotic PM women 20 2002
14. Osteoporosis Phase III. Osteoporotic PM women 12 2003
15. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 3 2003
16. Upper Respiratory Tract Infection Phase III. Patients with Acute Bronchitis 153 2003
17. Hyperlipidemia Phase III. Patients with heart failure 10 2004
18. Osteoporosis Phase III. Osteoporotic PM women 23 2004
19. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 3 2004
20. Prostata Cancer Phase III. Patients with prostata cancer 11 2004
21. Osteoporosis Phase III. Osteoporotic PM women 20 2004
22. Osteoporosis Phase III. Osteoporotic PM women 44 2004
23. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 10 2005
24. Chronic Renal Disease Phase III. Type 2 Diabetic Pateints with renal disease 7 2005
25. Osteoporosis Phase III. Osteoporotic PM women 6 2005
26. Hypertension Phase III. Hypertensive patients with microalbuminuria 2 2005
27. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 3 2005
28. Obesity Phase III. Obese patients 20 2005
29. Osteoporosis Phase III. Osteoporotic PM women 19 2005
30. Hyperlipidemia Phase III. Patients with dislipidaemia 8 2006
31. Hyperlipidemia Phase III. Patients with hypercholesteraemia and moderate proteinuria 5 2006
32. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 4 2006
33. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 6 2006
34. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 10 2006
35. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 7 2006
36. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 2 2006
37. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 1 2007
38. Hyperlipidemia Phase III. Dislipidemic patients 4 2007
39. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 10 2007
40. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 8 2007
41. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 24 2007
42. Gastroenterology Phase III. Patients with Erosive Gastroesophageal Reflux 16 2008
43. Osteoporosis Phase III. Osteoporotic PM women 7 2008
44. Hyperlipidemia Phase III. Dislipidemic patients 6 2008
45. Chronic Renal Disease Phase III. Chronic renal insufficiency 6 2008
46. Chronic Renal Disease Phase III. Chronic renal insufficiency 8 2008
47. Hyperlipidemia Phase III. Dislipidemic patients 18 2008
48. Hyperlipidemia Phase III. Patients with hypercholesterinemia 9 2008
49. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 10 2008
50. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 40 2008
51. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 15 2008
52. Cardiovascular Outcome Phase III. Patients with Type 2 Diabetes and CAD 65 2008
53. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 18 2009
54. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 7 2009
55. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 18 2009
56. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes and hypercholesterinaemia 37 2009
57. Heart Failure Phase III. Patients with heart failure 5 2009
58. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes and hyperlipidaemia 10 2009
59. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 5 2009
60. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 11 2010
61. Type 2 Diabetes Phase III. Type 2 Diabetes 130 2010
62. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 16 2010
Therapeutic Area Type of Study Patient population No. of Enrolled Patients Year of Start
63. Osteoporosis Phase III. Osteoporotic Patients 2 2010
64. Cardiovascular Outcome Phase III. Patients with Type 2 Diabetes and CAD 44 2010
65. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 9 2010
66. RA, Biology Therapy Phase III. RA patients 1 2010
67. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 17 2010
68. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 12 2010
69. Rheumatoid Arthritis Phase III. RA patients 6 2011
70. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 5 2011
71. Hyperlipidemia Phase III. Patients with hypertrigliceridemia 1 2011
72. Diabetes Mellitus Phase III. Patients with Type 2 Diabetes 3 2011
73. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 7 2011
74. Cardiovascular Outcome Phase III. Patients with Type 2 Diabetes and CAD 63 2012-2017
75. Cardiovascular Outcome Phase III. Patients with Type 2 Diabetes and CAD 49 2012-2018
76. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 1 2012
77. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 5 2012
78. Metabolism Phase III. Patients with Hyperpotassaemia 2 2013
79. Hyperlipidemia, Biology Therapy Phase III. Patients with hypercholesterinaemia 54 2013-2017
80. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 12 2013
81. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 4 2013
82. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 12 2013
83. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 16 2013
84. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 3 2013-2016
85. RA, Biology Therapy Phase III., Biosimilar RA patients 1 2013
86. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 22 2013
87. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 5 2013
88. Cardiovascular Outcome (anticoagulant) Phase III. MI or PAD patients 73 2013-ongoing
89. Cardiovascular Outcome (anticoagulant) Phase III. MI or PAD patients 5 2015-ongoing
90. Rheumatoid Arthritis, Biological Therapy Phase III., Biosimilar RA patients 3 2014
91. Cardiovascular Outcome Phase III. Patients with Type 2 Diabetes 28 2014-2018
92. Multiple sclerosis Phase III. Patients with MS 6 2014-2016
93. Multiple sclerosis Phase III. Patients with MS 5 2014-2015
94. Cardiovascular Prevention Phase IIIb Patients with Type 2 Diabetes 15 2014-2018
95. Cardiovascular Outcome Phase III. Patients at high or very high risk of major CV events 31 2014-2017
96. Cardiovascular Outcome Phase III. Patients at high or very high risk of major CV events 14 2014-2017
97. Cardiovascular Outcome Phase III. Patients at high or very high risk of major CV events 19 2015-2017
98. Cardiovascular Outcome Phase III. Patients at high or very high risk of major CV events 13 2015-2017
99. Hyperlipidemia or mixed dyslipidemia Phase III. Patients with hyperlipidemia or mixed dyslipidemia 4 2014-2016
100. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 7 2014-2015
101. Hypertrigliceridemia Phase III. Patients with hypertrigliceridemia 4 2014
102. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 9 2014-2017
103. Type 2 Diabetes Phase III. Type 2 Diabetic Patients with renal disease 6 2014-2018
104. Osteoporosis Phase III. Osteoporotic patient 1 2014-2017
105. Rheumatoid Arthritis, Biological Therapy Phase III. Biosimilar RA patients 2 2014-2017
106. Rheumatoid Arthritis, Biological Therapy Phase III. Biosimilar RA patients 1 2015-2016
107. Diabetic Nephropathy Phase III. Patients with Type 2 Diabetes and nephropathy 2 2014-2016
108. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 12 2014-2016
109. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 2 2015-2016
110. Dermatology Phase III. Patients with Acne vulgaris 6 2015-2017
111. Cardiovascular Prevention Phase III. Patients at high or very high risk of major CV events 23 2015-ongoing
112. Type 2 Diabetes Phase III. Patients with Type 2 Diabetes 3 2015-2018
113. Gastroenterology Phase III. Patients with ulcerative cholitis 1 2015-2018
114. Gastroenterology Phase III. Patients with ulcerative cholitis 6 2015-2018
115. Type 2 Diabetes Phase III b Patients with Type 2 Diabetes 12 2015-2017
116. Pulmonology Phase III b Patients with COPD 3 2015-2017
117. Type 2 Diabetes Phase III Patients with Type 2 Diabetes 10 2015-ongoing
118. Dermatology Phase III Patients with Psoriatic arthiritis 2 2015-2017
119. Type 2 Diabetes Phase III Patients with Type 2 Diabetes chronic kidney disease 2 2015-ongoing
120. Type 2 Diabetes Phase III Patients with Type 2 Diabetes renal disease 4 2015-ongoing
121. Type 2 Diabetes Phase III Patients with Type 2 Diabetes 7 2016-2018
122. Type 2 Diabetes Phase III b Patients with Type 2 Diabetes 5 2015-2016
123. Rheumatology Phase III RA patients 2 2012-2017
124. Neurology Phase III SM Patients 6 2014-2018
125. Rhematology Phase III RA patients 2 2014-2016
126. Type 1 Diabetes Phase III Patients with Type 1 diabetes 1 2015-2017
127. Gastroenterology Phase III Patients with ulcerative cholitis 5 2016-ongoing
128. Gastroenterology Phase III Patients with chron disease 1 2016-2017
129. Dermatology Phase III Patients with Acne vulgaris 15 2017
Therapeutic Area Type of Study Patient population No. of Enrolled Patients Year of Start
130. Hyperlipidemia Phase III Patients with hyperlipidemia 1 2017-2018
131. Allergy Phase III Patients with allergic rhinitis 6 2016-2018
132. Type 2 Diabetes Phase III Patients with Type 2 Diabetes 15 2017-2018
133. Type 2 Diabetes Phase III Patients with Type 2 Diabetes 5 2017-2018
134. Type 2 Diabetes Phase III Patients with Type 2 Diabetes 5 2017-2018
135. Rheumatology Phase III RA patients 4 2017-2018
136. Rheumatology Phase III RA patients 7 2017-2019
137. Rheumatology Phase IIIb/IV RA patients 2 2017-2018
138. Type 1 Diabetes Phase III Patients with Type 1 diabetes 4 2017-2018
139. Type 1 Diabetes Phase III Patients with Type 1 diabetes 3 2017-2018
140. Type 2 Diabetes Phase III CV outcomes 13 2017-ongoing
141. Heart Failure Phase III Patients with chronic heart failure 13 2017-ongoing
142. Hyperlipidemia Phase III Hypertrigliceridemia with normal renal function 9 2017-ongoing
143. Hyperlipidemia Phase III Hypertrigliceridemia with normal renal function 5 2017-ongoing
144. Hyperlipidemia Phase III Hypertrigliceridemia with mild or moderate renal function 3 2017-ongoing
145. Hyperlipidemia Phase III Hypertrigliceridemia with mild or moderate renal function 1 2017-2018
146. Type 2 Diabetes Phase III Patients with Type 2 Diabetes 10 2017-ongoing
147. Vaccine study Phase III Chlostridium difficile vaccine in adults 50 years and older 122 2017-ongoing
148. Type 2 Diabetes Phase III T2DM with CV outcomes by reducing triglycerides in DM 30 2017-ongoing
149. Rheumatology Phase III RA patients 3 2017-ongoing
150. Rheumatology Phase III RA patients 7 2017-ongoing
151. Gastroenterology Phase III Patients with ulcerative cholitis 2 2018-ongoing
152. Type 2 Diabetes Phase III Patients with Type 2 diabetes mellitus 7 2018-ongoing
153. Type 2 Diabetes Phase III Patients with Type 2 diabetes mellitus 23 2018-ongoing
154. Hyperlipidemia Phase III CV patients with Statin intolerance 15 2018-ongoing
155. Hyperlipidemia Phase III CV patients with Statin intolerance 7 2018-ongoing
156. Hyperlipidemia Phase III CV patients with Statin intolerance 1 2018-ongoing
157. Vaccine study Phase III Influenza vaccine in older adults and elderly 14 2018-ongoing
158. Type 2 Diabetes Phase III Patients with Type 2 diabetes 17 2018-ongoing
159. Rheumatology Phase III RA patients 7 2017-2018
Print Friendly, PDF & Email